We thank Dr Summers et al. for their interest in our recent report 1 on the emergence of a clone of Wilm's tumour 1 (WT1) mutated AML blasts in a paediatric patient. Their data 2 support and considerably extend our data and argue for further studies in this increasingly interesting gene.
We have two comments: first, in the LeukemiaNet Work Package on minimal residual disease detection, the primer set, developed in our lab and initially selected for further studies owing to its superior performance in multicenter testings, was replaced by another owing to fears of further mutations within the amplified region (http://www.leukemia-net.org/content/e62/ e892/e893/index_eng.html). This has now been shown to be the case by Summers et al. Children with acute lymphoblastic leukemia (ALL), who have central venous lines (CVL) early inserted during induction therapy including steroid and Escherichia coli L-asparaginase (L-Asp), are at high risk of developing CVL venous thrombosis (CVL-VT).
1-3 Data on occurrence, risk factors and outcome of CVL-VT, as well as the gold-standard imaging test, are either limited or controversial. [1] [2] [3] [4] A recent meta-analysis on thrombotic events in childhood ALL could not thoroughly evaluated the role of CVL as the proportion of patients bearing a CVL was reported by few prospective studies. 4 Recognizing the risk factors of CVL-related complications is important for assessing the benefit/risk ratio of these devices. We prospectively evaluated the occurrence and risk factors of CVL-VT detected by spiral computed tomography (CT) and ultrasound (US) in 70 consecutive children with ALL, who had CVL inserted within 2 weeks from starting chemotherapy. The induction therapy included steroid (4 weeks), vincristine and daunorubicin (4 doses, weekly), E. coli L-Asp (eight doses of 5000 UI/m 2 , every 3 days) and intrathecal (IT) chemotherapy, followed by 6-mercaptopurine, cytarabine, cyclophosphamide and IT chemotherapy. From January to August 2000 patients were enroled in the Associazione Italiana di Emato-Oncologia Pediatrica (AIEOP) ALL 95 study, thereafter in the AIEOP ALL 2000. The major differences between the two studies were randomization to PDN or dexamethazone (DXM) until day þ 28
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Figure 1
Depiction of the five selected polymorphisms in WT1 with refSNP ID numbers and heterozygous sequences shown. Black boxes: WT1 exon 1-10.
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